Table 1.
Population Characteristics at Baseline
| Age (Years) | Frequency (n=21) | % |
|---|---|---|
| 31–40 | 1 | 4.76% |
| 41–50 | 5 | 23.81% |
| 51–60 | 9 | 42.86% |
| 61–70 | 6 | 28.57% |
| Gender | ||
| Female | 13 | 61.90% |
| Male | 8 | 38.10% |
| Body Mass Index (kg/m2) | ||
| Ideal weight 18.5 to 24.9 kg/m2 | 2 | 9.52% |
| Overweight 25 to 29.9 kg/m2 | 10 | 47.62% |
| Grade I obesity 30 to 34.9 kg/m2 | 8 | 38.10% |
| Grade II obesity 35 to 35.9 kg/m2 | 1 | 4.76% |
| Comorbidities | ||
| Aspirin-exacerbated respiratory disease | 5 | 23.81% |
| Allergic rhinitis (AR) | 9 | 42.86% |
| AR + CRSwNP | 3 | 14.29% |
| Other | 4 | 19.05% |
| Prior biologic | ||
| Yes | 7 | 33.33% |
| Omalizumab | 7 | 100% |
| No | 14 | 66.67% |
| Pulmonary obstruction severity by FEV1 | ||
| Mild | 14 | 66.67% |
| Moderate | 1 | 4.76% |
| Moderately severe | 4 | 19.05% |
| Severe | 2 | 9.52% |
Abbreviations: CRSwNP, Chronic rhinosinusitis associated with nasal polyp; AR, Allergic rhinitis; kg, Kilograms; m2, square meter; FEV1, Forced expiratory volume.